Last quarter (Q2 2024), InMed Pharmaceuticals's total revenue was $1.24M, an increase of 163.99% from the same quarter last year. In Q2, InMed Pharmaceuticals's net income was $-1.48M. See InMed Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 23	Jun 22	Jun 21	Jun 16	Jun 14
Total Revenue	$ 5.49M	$ 4.14M	$ 1.09M	-	$ 0.00	$ 0.00
Cost of Revenue	$ 3.65M	$ 2.73M	$ 545.89K	-	-	-
Gross Profit	$ 1.84M	$ 1.40M	$ 543.55K	-	-	-
Operating Expense	$ 9.10M	$ 9.78M	$ 15.65M	$ 9.94M	$ 1.84M	$ 1.15M
Operating Income	$ -7.26M	$ -8.38M	$ -15.11M	$ -9.94M	$ -1.84M	$ -1.15M
Net Non Operating Interest Income Expense	$ 606.86K	$ 492.44K	$ 96.09K	$ 344.33K	-	$ 0.00
Other Income Expense	$ -247.60K	-	-	$ 79.53K	$ -25.00	$ -846.00
Pretax Income	$ -6.35M	$ -7.93M	$ -18.60M	$ -10.20M	$ -1.84M	$ -1.15M
Tax Provision	$ 3.30K	$ 13.10K	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -6.35M	$ -7.95M	$ -18.60M	$ -10.20M	$ -1.84M	$ -1.15M
Basic EPS	$ -1.65	$ -3.25	$ -33.17	$ -950.00	$ -1.02	$ -1.24
Diluted EPS	$ -1.65	$ -3.25	$ -33.17	$ -950.00	$ -1.02	$ -1.24
Basic Average Shares	$ 17.93M	$ 2.45M	$ 560.83K	$ 10.75K	$ 1.82M	$ 1.05M
Diluted Average Shares	$ 17.93M	$ 2.45M	$ 560.83K	$ 10.75K	$ 1.82M	$ 1.05M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	$ 67.20K	$ 45.97K
Total Expenses	$ 12.75M	$ 12.51M	$ 16.20M	$ -9.94M	$ 1.84M	$ 1.15M
Net Income From Continuing And Discontinued Operation	$ -6.35M	$ -7.95M	$ -18.60M	$ -10.20M	$ -1.84M	$ -1.15M
Normalized Income	$ -4.93M	$ -5.83M	$ -10.20M	$ -7.50M	$ -1.84M	$ -1.15M
Interest Expense	-	-	-	-	-	-
EBIT	$ -6.35M	$ -7.93M	$ -18.60M	$ -9.84M	$ -1.84M	$ -1.15M
EBITDA	$ -5.75M	$ -7.34M	$ -18.09M	$ -9.61M	$ -1.77M	$ -1.15M

Currency in USD

InMed Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing